Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Gallardo, Miguel ^a,b   Barrio, Santiago ^a   Fernandez, Marisol ^c   Paradela, Alberto ^c   Arenas, Alicia ^a   Toldos, Oscar ^a   Ayala, Rosa ^a   Albizua, Enriqueta ^d   Jimenez, Ana ^a   Redondo, Santiago ^e   Garcia Martin, Rosa M ^a   Gilsanz, Florinda ^a   Albar, Juan P ^c   Martinez Lopez, Joaquin ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e Hematology Service Nuestra Señora de Sonsoles   (Spain)

Author keywords

2D DIGE MS; Essential thrombocythemia; HSP70; Polycythemia vera

Indexed keywords

HEAT SHOCK PROTEIN 70; JANUS KINASE 2; SMALL INTERFERING RNA; STAT5 PROTEIN; TRANSCRIPTION FACTOR GATA 1;

AGED; APOPTOSIS; ARTICLE; BIOINFORMATICS; BURST FORMING UNIT E; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; ERYTHROID PRECURSOR CELL; ESSENTIAL THROMBOCYTEMIA; EX VIVO STUDY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYCYTHEMIA VERA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; THROMBOCYTHEMIA; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ERYTHROID CELLS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PROTEOMICS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84887656542     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-142     Document Type: Article

References (35)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148. 10.1038/nature03546, 15793561.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779-1790. 10.1056/NEJMoa051113, 15858187.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397. 10.1016/j.ccr.2005.03.023, 15837627.
5. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005, 106(10):3374-3376. 10.1182/blood-2005-05-1889, 16081684.
6. Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, et al. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol 2007, 35(11):1695-1703. 10.1016/j.exphem.2007.07.004, 2270411, 17764814.
7. Puigdecanet E, Espinet B, Lozano JJ, Sumoy L, Bellosillo B, Arenillas L, et al. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia 2008, 22(7):1368-1376. 10.1038/leu.2008.112, 18480837.
8. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009, 59(3):171-191. 10.3322/caac.20009, 19369682.
9. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008, 83(6):491-497. 10.1002/ajh.21183, 18429051.
10. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366(9):799-807. 10.1056/NEJMoa1110557, 22375971.
11. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013, 31(10):1285-1292. 10.1200/JCO.2012.44.4489, 23423753.
12. Issaq H, Veenstra T. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): advances and perspectives. Biotechniques 2008, 44(5):697-698. 700.
13. Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010, 120(10):3578-3593. 10.1172/JCI42442, 2947224, 20852385.
14. Schmitt E, Parcellier A, Gurbuxani S, Cande C, Hammann A, Morales MC, et al. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res 2003, 63(23):8233-8240.
15. Dix DJ, Allen JW, Collins BW, Mori C, Nakamura N, Poorman-Allen P, et al. Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc Natl Acad Sci U S A 1996, 93(8):3264-3268. 10.1073/pnas.93.8.3264, 39594, 8622925.
16. Zermati Y, Garrido C, Amsellem S, Fishelson S, Bouscary D, Valensi F, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001, 193(2):247-254. 10.1084/jem.193.2.247, 2193347, 11208865.
17. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007, 81(1):15-27.
18. Song J, Takeda M, Morimoto RI. Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth. Nat Cell Biol 2001, 3(3):276-282. 10.1038/35060068, 11231577.
19. Gotz R, Kramer BW, Camarero G, Rapp UR. BAG-1 haplo-insufficiency impairs lung tumorigenesis. BMC Cancer 2004, 4:85. 10.1186/1471-2407-4-85, 539250, 15560850.
20. Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, et al. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. Br J Haematol 2013, 161(5):667-676. 10.1111/bjh.12308, 23560534.
21. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000, 2(8):469-475. 10.1038/35019501, 10934466.
22. Ebong IO, Morgner N, Zhou M, Saraiva MA, Daturpalli S, Jackson SE, et al. Heterogeneity and dynamics in the assembly of the heat shock protein 90 chaperone complexes. Proc Natl Acad Sci U S A 2011, 108(44):17939-17944. 10.1073/pnas.1106261108, 3207645, 22011577.
23. Sims JD, McCready J, Jay DG. Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 2011, 6(4):e18848. 10.1371/journal.pone.0018848, 3077417, 21533148.
24. Schevchenko VA, Akayeva EA, Yeliseyeva IM, Yelisova TV, Yofa EL, Nilova IN, et al. Human cytogenetic consequences of the Chernobyl accident. Mutat Res 1996, 361(1):29-34. 10.1016/S0165-1161(96)90226-5, 8816940.
25. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115(15):3109-17. 10.1182/blood-2009-04-214957, 20130243.
26. Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009, 114(14):3018-3023. 10.1182/blood-2009-03-209916, 19541820.
27. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006, 108(4):1377-1380. 10.1182/blood-2005-11-009605, 16675710.
28. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006, 107(10):4139-41. Epub 2006, 10.1182/blood-2005-09-3900, 1895292, 16434490.
29. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007, 35(1):32-38.
30. Beer PA, Jones AV, Bench AJ, Goday-Fernandez A, Boyd EM, Vaghela KJ, et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009, 144(6):904-908. 10.1111/j.1365-2141.2008.07560.x, 19170680.
31. Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111(7):3863-3866. 10.1182/blood-2007-09-111971, 18195094.
32. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-2301. 10.1056/NEJMoa0810069, 19474426.
33. Murphy ME. The HSP70 family and cancer. Carcinogenesis 2013, 34(6):1181-8. 10.1093/carcin/bgt111, 23563090.
34. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93(3):385-395. 10.1016/S0092-8674(00)81167-8, 9590173.
35. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011, 365(15):1455-7. 10.1056/NEJMc1109555, 21995409.